Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus
Disc Medicine shares rose 3.3% to $79.41 in the final 2025 U.S. trading session, ahead of an FDA decision expected by late January on its lead drug bitopertin for EPP. The stock has been volatile since reports of FDA skepticism on efficacy. No new company announcements were made. Broader biotech indexes ended mixed as markets closed for the New Year’s holiday.